Radiopharmaceutical supply disruptions and the use of Tc-99m-hydroxymethylene diphosphonate as an alternative to Tc-99m-pyrophosphate for the diagnosis of transthyretin cardiac amyloidosis
- Resource Type
- Authors
- Edward J. Miller; Roxana Campisi; Nishant R. Shah; Sean McMahon; Sarah Cuddy; Cesia Gallegos-Kattan; Mathew S. Maurer; Thibaud Damy; Riemer H. J. A. Slart; Ketan Bhatia; Andrew J. Einstein
- Source
- Journal of Nuclear Cardiology, 29. SPRINGER
- Subject
- transthyretin cardiac amyloidosis
cardiovascular system
HMDP, hydroxymethylene diphosphonate, PYP, pyrophosphate, cardiac amyloidosis, Radiopharmaceutical, supply disruption, PYP shortage
Radiology, Nuclear Medicine and imaging
Tc-99m-hydroxymethylene diphosphonate
ETIOLOGIC DIAGNOSIS
SCINTIGRAPHY
Cardiology and Cardiovascular Medicine
radiopharmaceutical supply
- Language
- English
- ISSN
- 1071-3581
Amid pyrophosphate shortage, the American Society of Nuclear Cardiology issues an information statement on how to use HMDPas an alternative radiopharmaceutical in cardiac amyloidosis imaging.Early diagnosis of ATTR cardiac amyloidosis must not be jeopardized.